447 related articles for article (PubMed ID: 17341562)
1. The impact of pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly.
Lindberg-Larsen R; Møller N; Schmitz O; Nielsen S; Andersen M; Orskov H; Jørgensen JO
J Clin Endocrinol Metab; 2007 May; 92(5):1724-8. PubMed ID: 17341562
[TBL] [Abstract][Full Text] [Related]
2. Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly.
Higham CE; Rowles S; Russell-Jones D; Umpleby AM; Trainer PJ
J Clin Endocrinol Metab; 2009 Jul; 94(7):2459-63. PubMed ID: 19366854
[TBL] [Abstract][Full Text] [Related]
3. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
[TBL] [Abstract][Full Text] [Related]
4. Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant.
Drake WM; Rowles SV; Roberts ME; Fode FK; Besser GM; Monson JP; Trainer PJ
Eur J Endocrinol; 2003 Dec; 149(6):521-7. PubMed ID: 14640992
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant.
Sesmilo G; Fairfield WP; Katznelson L; Pulaski K; Freda PU; Bonert V; Dimaraki E; Stavrou S; Vance ML; Hayden D; Klibanski A
J Clin Endocrinol Metab; 2002 Apr; 87(4):1692-9. PubMed ID: 11932303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance.
Colao A; Pivonello R; Auriemma RS; De Martino MC; Bidlingmaier M; Briganti F; Tortora F; Burman P; Kourides IA; Strasburger CJ; Lombardi G
Eur J Endocrinol; 2006 Mar; 154(3):467-77. PubMed ID: 16498061
[TBL] [Abstract][Full Text] [Related]
7. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
[TBL] [Abstract][Full Text] [Related]
8. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cortisol metabolism by the growth hormone receptor antagonist pegvisomant in patients with acromegaly.
Trainer PJ; Drake WM; Perry LA; Taylor NF; Besser GM; Monson JP
J Clin Endocrinol Metab; 2001 Jul; 86(7):2989-92. PubMed ID: 11443156
[TBL] [Abstract][Full Text] [Related]
10. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
[TBL] [Abstract][Full Text] [Related]
11. [Pegvisomant--growth hormone receptor antagonist in the treatment of acromegaly].
Zgliczyński W; Zdunowski P
Endokrynol Pol; 2007; 58(5):408-16. PubMed ID: 18058736
[TBL] [Abstract][Full Text] [Related]
12. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
[TBL] [Abstract][Full Text] [Related]
13. The effect of pegvisomant-induced serum IGF-I normalization on serum leptin levels in patients with acromegaly.
Parkinson C; Whatmore AJ; Yates AP; Drake WM; Brabant G; Clayton PE; Trainer PJ
Clin Endocrinol (Oxf); 2003 Aug; 59(2):168-74. PubMed ID: 12864793
[TBL] [Abstract][Full Text] [Related]
14. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
15. Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients.
Madsen M; Poulsen PL; Orskov H; Møller N; Jørgensen JO
J Clin Endocrinol Metab; 2011 Aug; 96(8):2405-13. PubMed ID: 21632808
[TBL] [Abstract][Full Text] [Related]
16. Fat content in liver and skeletal muscle changes in a reciprocal manner in patients with acromegaly during combination therapy with a somatostatin analog and a GH receptor antagonist: a randomized clinical trial.
Madsen M; Krusenstjerna-Hafstrøm T; Møller L; Christensen B; Vendelbo MH; Pedersen SB; Frystyk J; Jessen N; Hansen TK; Stødkilde-Jørgensen H; Flyvbjerg A; Jørgensen JO
J Clin Endocrinol Metab; 2012 Apr; 97(4):1227-35. PubMed ID: 22298804
[TBL] [Abstract][Full Text] [Related]
17. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal.
Parkinson C; Kassem M; Heickendorff L; Flyvbjerg A; Trainer PJ
J Clin Endocrinol Metab; 2003 Dec; 88(12):5650-5. PubMed ID: 14671148
[TBL] [Abstract][Full Text] [Related]
18. Clinical use of pegvisomant for the treatment of acromegaly.
Drake WM; Trainer PJ
Treat Endocrinol; 2003; 2(6):369-74. PubMed ID: 15981941
[TBL] [Abstract][Full Text] [Related]
19. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant.
Barkan AL; Burman P; Clemmons DR; Drake WM; Gagel RF; Harris PE; Trainer PJ; van der Lely AJ; Vance ML
J Clin Endocrinol Metab; 2005 Oct; 90(10):5684-91. PubMed ID: 16076947
[TBL] [Abstract][Full Text] [Related]
20. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
